FDA panel votes against approving Intellipharma's opioid painkiller

(Reuters) - A panel of independent advisers to the U.S. Food and Drug Administration concluded on Wednesday that there is not enough evidence to support the approval of Intellipharmaceutics International Inc's long-acting opioid painkiller.